MARCUS SCHABACKER, M.D., PH.D. - Corporate Board Profile

Enveric Biosciences, Inc.

Filing Date	Source Excerpt
2022-09-23	Dr. Marcus Schabacker has served as a non-employee director of the Company since December 30, 2020. Since January 2018, Dr. Schabacker has served as president and chief executive officer of the ECRI Institute, a non-profit organization with 500 employees and an operating budget of $80 million focusing on advancing evidenced-based, effective healthcare globally. Prior to joining ECRI, Dr. Schabacker worked at Baxter Healthcare Corporation, serving as corporate vice president and chief scientific officer from July 2015 to May 2017, chairman of the executive quality council from March 2014 to May 2017, Chief Scientific Officer, Medical Products from July 2014 to July 2015, and Vice President, R&D, Medical Products from March 2011 to July 2014. During his clinical years, and his time as an industry thought leader, Dr. Schabacker was focused on patient safety and enhancing patient care. For over a decade Dr. Schabacker has served on numerous boards of small and midsize companies and organizations, providing management with guidance and expertise to strategically accelerate growth and to build successful and sustainable high performing management teams. Dr. Schabacker’s medical background and relevant research and development experience qualify him to be a director of the Company. The following table presents the total compensation for each person who served as a member of our Board during the fiscal year ended December 31, 2021. Other than set forth in the table and described more below, we did not pay any compensation, reimburse any expense of, make any equity awards or non-equity awards to, or pay any other compensation to any of the other members of our Board in 2021. Marcus Schabacker 37,000 76,594 113,594 Consists of RSA’s equivalent to 320 shares of Common Stock, valued at $240.00 per share (the closing price per share on the date of the award). As of December 31, 2021, Marcus Schabacker had outstanding 320 RSA’s.
2023-09-18	Marcus Schabacker, M.D., Ph.D. has served as a non-employee director of the Company since December 30, 2020. Since January 2018, Dr. Schabacker has served as President and Chief Executive Officer of the ECRI Institute, a non-profit organization with 500 employees and an operating budget of $80 million focusing on advancing evidenced-based, effective healthcare globally. Prior to joining ECRI, Dr. Schabacker worked at Baxter Healthcare Corporation, serving as Corporate Vice President and Chief Scientific Officer from July 2015 to May 2017, chairman of the executive quality council from March 2014 to May 2017, Chief Scientific Officer, Medical Products from July 2014 to July 2015, and Vice President, R&D, Medical Products from March 2011 to July 2014. During his clinical years, and his time as an industry thought leader, Dr. Schabacker was focused on patient safety and enhancing patient care. For over a decade Dr. Schabacker has served on numerous boards of small and midsize companies and organizations, providing management with guidance and expertise to strategically accelerate growth and to build successful and sustainable high performing management teams. Dr. Schabacker’s medical background and relevant research and development experience qualify him to be a director of the Company.
2024-04-16	Marcus Schabacker, M.D., Ph.D. has served as a non-employee director of the Company since December 30, 2020. ... Dr. Schabacker has served as President and Chief Executive Officer of the ECRI Institute since January 2018. ... The following table presents the total compensation for each person who served as a non-employee director during the fiscal year ended December 31, 2023. ... Marcus Schabacker 52,000 ... The following table sets forth the membership of each of the Board committees listed above. ... Marcus Schabacker Audit Committee, Compensation Committee, Science and Technology Committee Chairman.
2024-12-18	Marcus Schabacker, M.D., Ph.D. (6) All share amounts consist of Common Stock.